A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer

Jennifer Gill, Jeremy Paul Cetnar, Vinay Prasad

Research output: Contribution to journalShort surveypeer-review

2 Scopus citations

Abstract

In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this setting and further research on overall survival benefit is needed to prove drug efficacy.

Original languageEnglish (US)
Pages (from-to)736-738
Number of pages3
JournalTrends in Cancer
Volume6
Issue number9
DOIs
StatePublished - Sep 2020

Keywords

  • FDA
  • immunotherapy
  • small cell lung cancer
  • surrogate endpoints

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this